ESC 365 - Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial

Open Access

Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial

Session: Phenotyping in hypertrophic cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor Z. Tian (Beijing, CN)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Zhuang Tian

Peking Union Medical College Hospital, Beijing (China)

1 presentation

1 follower

6 more presentations in this session

Sudden cardiac death HCM risk scores in apical hypertrophic cardiomyopathy: an unmet need in clinical practice

Speaker: Doctor D. Da Silva Correia (Lisbon, PT)

Left ventricular global deformation index, evaluating a novel echocardiographic marker for prediction of heart failure in asian patients with hypertrophic cardiomyopathy

Speaker: Doctor T. Li (Singapore, SG)

Genetic influences on clinical outcomes in hypertrophic cardiomyopathy: comparative insights into MYH7, MYBPC3 and TPM1 gene mutations

Speaker: Doctor M. Vilela (Lisbon, PT)

A de novo systematic literature review to identify the clinical effectiveness and safety of different treatments for patients with non-obstructive hypertrophic cardiomyopathy

Speaker: Mr M. Hurst (Pontyclun, GB)

Real-world clinical and economic outcomes of nonobstructive hypertrophic cardiomyopathy: a german claims data analysis

Speaker: Associate Professor F. Sedaghat-Hamedani (Heidelberg, DE)

Access the full session

Phenotyping in hypertrophic cardiomyopathy

Speakers: Doctor Z. Tian, Doctor D. Da Silva Correia, Doctor T. Li, Doctor M. Vilela, Mr M. Hurst...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources